Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040360 · ClinicalTrials.gov registry record · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
A Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT05040360: Recruiting Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor, sponsored by SWOG Cancer Research Network.
NCT05040360 is a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 141 participants, above the 81-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05040360, a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Primary Outcome
Distribution of RFS in each arm will be estimated using the method of Kaplan-Meier and compared using the stratified log rank test.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Temozolomide
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Tower Cancer Research Foundation - Beverly Hills
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What NCT05040360 shows while recruiting
NCT05040360 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (74% higher).
The record links to 5 conditions, with Metastatic Malignant Neoplasm in the Liver appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT05040360 names 20 study sites across 4 states, led by Alaska, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05040360 about?
NCT05040360 is a clinical study titled "Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors". This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either ...
What is the current status of trial NCT05040360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2022-05-05. Estimated completion is 2027-03-31.
What conditions does trial NCT05040360 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8.
What interventions are being tested in trial NCT05040360?
The interventions under investigation include: Capecitabine (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT05040360?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040360 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05040360's enrollment target sits among peer trials
141 2nd of 13 the highest of 13 other Metastatic Malignant Neoplasm in the Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm in the Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
RECRUITING · Phase 2
-
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05814146 · 141 participants · NA
Trial of Variable Dialysate Bicarbonate
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI